Get the Stockscreener App
8.84
0.80%
-0.019
Actuate Therapeutics Inc stock is traded at $8.84, with a volume of 14,236.
It is down -0.80% in the last 24 hours and up +7.89% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$8.821
Open:
$8.81
24h Volume:
14,236
Relative Volume:
0.26
Market Cap:
$174.22M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.10%
1M Performance:
+7.89%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$8.39
$8.92
1-Week Range:
$8.39
$9.9499
52-Week Range:
$5.51
$11.73
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.76 | 174.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.58 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
713.96 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.08 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.20 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.33 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Actuate Therapeutics' Lock-Up Period Will Expire on February 10th (NASDAQ:ACTU) - MarketBeat
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Actuate Therapeutics’ (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10th - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading Down 5.4%Here's What Happened - MarketBeat
Trump 2.0: This Sector May See A Big Performance Boost - The Globe and Mail
Algonquin Power & Utilities Corp. Announces Leadership Transition - The Globe and Mail
Myelofibrosis Clinical Trials, Pipeline Analysis, EMA, PDMA, - openPR
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Bone metastasis in Solid Tumor Market Expected to rise, 2034 | Mabwell Bioscience Co., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics, Actuate Therapeutics - Barchart
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Bone metastasis in Solid Tumor Market Expected to rise, 2034 | - openPR
TOROMONT TO ANNOUNCE 2024 FULL YEAR AND FOURTH QUARTER RESULTS ON FEBRUARY 11, 2025 - The Globe and Mail
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
The Best High-Yield Energy Stock to Invest $200 in Right Now - The Globe and Mail
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
3 Artificial Intelligence (AI) Stocks That Could Go on a Multidecade Run - The Globe and Mail
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
EMA gives OMPD to Actuate’s pancreatic cancer therapy - MSN
Here's How Much Money You'd Have if You Invested $10,000 in Nvidia a Decade Ago - The Globe and Mail
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.1%What's Next? - MarketBeat
EMA grants orphan drug designation to Actuate's cancer drug - Investing.com
Actuate Therapeutics Receives EMA Orphan Medicinal Product - GlobeNewswire
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer - Yahoo Finance
Is Raytheon the Best Defense and Aerospace Stock to Own in 2025? - The Globe and Mail
Elraglusib can prolong survival in metastatic pancreatic cancer: Trial - Myeloma Research News
Pancreatic Cancer Market Growth Projections 2024-2034: DelveInsight Analysis - EIN News
Actuate reports breakthrough in pancreatic cancer trial By Investing.com - Investing.com South Africa
Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial - Yahoo Finance
Actuate reports breakthrough in pancreatic cancer trial - Investing.com
Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer - MarketWatch
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Actuate's Pancreatic Cancer Drug Shows Breakthrough 44% One-Year Survival Rate in Phase 2 Trial - StockTitan
Actuate Therapeutics (NASDAQ:ACTU) Trading 0.8% HigherShould You Buy? - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Ewing Sarcoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Patient Pool, Prevalence and Companies DelveInsight - The Globe and Mail
GXO Logistics: Time to Buy the Dip for the Rip in 2025 - The Globe and Mail
Actuate Therapeutics to be Added to Russell 2000® Index - The Manila Times
Actuate Therapeutics, oncology drug developer, sets terms for $50M IPO - MSN
Myelofibrosis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart
Palantir vs. Tesla: Which Growth Stock is a Better Buy Right Now? - The Globe and Mail
Mirdametinib Boosts Outcomes, QOL in NF1-PN - www.oncnursingnews.com/
FDA OKs Ninlotinib Tablets With No Mealtime Restrictions for CML - www.oncnursingnews.com/
FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma - www.oncnursingnews.com/
FDA grants rare disease status to Actuate's Ewing sarcoma drug By Investing.com - Investing.com Australia
FDA grants rare disease status to Actuate's Ewing sarcoma drug - Investing.com India
Actuate Therapeutics : FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - Marketscreener.com
Actuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - MarketWatch
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - The Manila Times
Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma - OncLive
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Actuate Therapeutics Inc Stock (ACTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bios Equity COF, LP | Director |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Bios Equity COF, LP | Director |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
| Fletcher Aaron G.L. | Director |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Fletcher Aaron G.L. | Director |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
| Kreis Leslie W. | 10% Owner |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Kreis Leslie W. | 10% Owner |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):